Purpose
Tumor vasculature is deemed to be a promising target for the treatment of solid cancerous lesions. Different therapeutic approaches, alone or combined, such as antiangiogenic therapy, chemo-, radio-and immunotherapy are currently refined in order to specifically interfere with blood vessel growth in the tumor (1) . This objective might be also achieved by a novel form of radiosurgery, known as Microbeam Radiation Therapy (MRT) (2) , which uses a particular irradiation geometry and X-rays generated in a synchrotron light source; the beam is spatially fractionated into an array of quasi-parallel planar microbeams which are a few tens microns wide and separated by a few hundred microns. This unique irradiation geometry allows very high dose (hectograys) deposition efficient for the treatment of brain tumors in small animals while ensuring an unusually high normal tissue tolerance, even in developing larger animals (3, 4) .
The preferential effect on malignant tissues has been mainly attributed to selective effects of microbeams on immature tumor vessels versus lack of microbeam effects on the differentiated normal vasculature (5) , although other factors might be operative. Lesions induced by the microbeams in the normal capillary network can be rapidly repaired (6, 7) and normal arteries are microbeam-resistant too (8) . Thus, there is no decrease in vessel density, blood volume, no hemorrhage and no ischemic necrosis after MRT in normal mammalian tissues. Conversely, no clear experimental proof of the effect of MRT on tumor vessels has been given in the literature. Our recent magnetic resonance imaging study failed to reveal important damage to tumor vessels after MRT (9) . Crossfired MRT slowed the growth of the heterologously implanted 9L gliosarcoma (9LGS) and the development of its vasculature. We now characterize the biological effects of 50 µm-wide microbeams, efficient in terms of tumor control and normal tissue sparing (10) , on normal rat brain and intracerebral 9LGS, Bouchet et al. 2010 4 particularly on growth and morphometric parameters of blood vessels from day 2 to day 45 after irradiation, and on the expression of the Vascular Endothelial Growth Factor.
Methods and Materials
All procedures related to animal care conformed to the Guidelines of the French Government with licenses 380325 and 380321. Rats were anesthetized with an intraperitoneal injection of xylazine/ketamine (64.5/5.4mg.kg -1 for irradiations) and 2.5% isoflurane (MRI follow-up) for maintenance.
Tumor inoculation
Transplantable 9LGS cells were implanted in 59, 10-week-old-Fisher rats weighing between 180 and 220g. Implantation procedure followed the protocol described in (10).
Briefly, 10 4 9LGS cells suspended in a 1μl DMEM medium were injected into the right caudate nucleus (3.5mm from the bregma) at a depth of 5.5mm from the dura.
Magnetic resonance imaging and group sorting
We used a 4.7T Bruker Avance console and volume/surface cross coil configuration.
Seven days after 9LGS implantation, rats underwent anatomical MRI (T 2 -weighted image) in order to sort them two groups with similar mean tumor size. Those 59 rats were divided into a control group (n=25) and a group of 34 rats and irradiated by MRT 10 days after 9LGS
implantation. Rats (n=4 to 8) underwent MRI and 4 of them were culled at each delay for biological studies. The survival curves were established using 9 rats of each group. The number of days elapsed after implantation (n) and treatment (m) is designated as D n T m .
Radiation source and irradiation geometry
Irradiations were performed on the ID17 biomedical beamline at the European Synchrotron
Radiation Facility using X-rays emitted tangentially from relativistic electron bunches circulating in a storage ring. The wiggler produces a wide spectrum of photons which extends from 50 over 350keV (median energy: 90keV). The quasi-laminar beam was shaped into an array (8mm wide) of rectangular, microscopically thin and quasi-parallel microbeams using a multislit collimator (11) . Rats in the treated group were irradiated (D 10 T 0 ) after tumor inoculation using two, 10mm high, arrays of 40 vertical, planar microbeams (width 50μm, 200μm on-center spacing), one anteroposterior, the other lateral, both focused for orthogonal intersection (crossfiring) in the anterior part of the right hemisphere, where the 9LGS was located. Before reaching and after leaving the volume of intersection enclosing the tumor, each array alone covered a volume of the rat's head in which it was unidirectional. Animals were aligned into the beam using 3 live cameras and the coordinates of the center of the microbeam arrays were 3.5mm left from the medio-lateral line, -6mm in the dorso-ventral direction from the skin surface and at the bregma point in the anterioposterior direction. The in-microbeam entrance dose was 400Gy per array, the mean dose rate ~16000Gy.s -1 .
Monte Carlo simulation and doses calculations
The doses were calculated by means of the Monte Carlo method normally used for MRT dose planning and quality assurance at the ESRF (12) . Further details of our MRT dosimetry protocols are provided as Supplementary Material.
Rat follow-up by MRI
Eight rats were imaged one day before (D 9 T -1 ) and animals from all groups at 2, 5, 8
15 and 45 days after MRT treatment. For each group, 4 rats were followed up and imaged at every time point. Four rats per groups were also imaged at every delay after irradiation and culled for immunohistological studies and western blot analysis.
Each MRI session (duration 1h15), detailed in the Supplementary material, was organized as follow:
-Anatomical T 2 -weighted images -BVf (blood volume fraction) and VSI (vessel size index) measurements -Vascular permeability of P846 (Gd-based contrast agent) measurements
MRI data analysis
BVf, VSI and vessel permeability maps were computed pixel by pixel using an inhouse program developed under Matlab (MathWorks, NA). BVf and VSI were calculated as described previously (13, 14) . Null pixels were excluded in the mean calculation in order to
give information only on perfused brain regions. Vessel permeability was estimated by subtracting the peak MR signal obtained after the injection of Gd-DOTA from the peak MR signal measured before injection and expressed as a percentage of contrast enhancement.
Three regions of interest (ROIs) were manually delineated on the T 2 -weighted image on which the tumor appeared the largest (see fig. 1 ) i) the whole tumor, ii) the ipsilateral (right)
hemisphere without tumor and iii) the contralateral hemisphere, and reported on the other maps. Tumor and surrounding parts of the normal brain in the right hemisphere were exposed to the two intersecting arrays, normal brain parts of the left hemisphere unidirectionally to the lateral array alone. Tumor volumes were determined by multiplying the pixel size by the number of "tumoral pixels" on all MR slices on which the tumor was visible. Two 
Immuno / histological analyses (IHC)
Type-IV collagen (C IV ), a protein constituent of the vessel basal lamina, and RECA-1 (Rat Endothelial Cell Antigen), an antigen of endothelial cells, were labeled as previously described (7, 15) . Cell proliferation activity was assessed by means of Ki67 labeling. Further details of our IHC protocols and quantification are provided as Supplementary Material.
Western blot analysis of VEGF
The western blot protocol of VEGF is described in the Supplementary Material section.
Results
The main results of this study are summarized in table 1. Radiation doses were calculated in a rat head phantom using Monte Carlo simulations. The peak dose deposited at 1cm depth in rat brain was 350/700Gy, generating a valley dose of 12.5/25Gy in the unidirectionally/bidirectionally irradiated brain regions respectively. Figure 1C shows the Kaplan-Meier representation of the survival of untreated and MRT-treated 9LGS bearing rats. MRT significantly increased the MST (mean survival time)
Survival curves
of treated animals compared with the control group of non-irradiated rats (65 days versus 20, respectively, log rank test: p=0.003). Thereafter, the evaluation of tumor volume using on T 2 -weighted MR images became more problematic since 2 rats did not exhibit tumor anymore (the hyposignal as shown in figure   1Ah was taken into account for lesion size determination); 2 rats showed small tumors and 1 rat a recurrent tumor comparable to those measured in control rats at D 18 T 8 .
MRT effects on 9LGS growth

MRT effects on 9LGS proliferative activity
The analyses Ki67 immunolabeling and HE stained sections revealed that MRTinduced damages were detectable from D 15 
Vessel size index
VSI values increased similarly in both irradiated and non irradiated tumors until D18, where they were significantly higher in tumors than in normal tissues (p<0.001). 
Contrast enhancement
Vessel permeability (indicated as contrast MR enhancement, figure 3 The use of 50 µm-wide microbeams significantly improved the MSTs for rats with 9LGS in our laboratory (15, 17) , notably in this study. This particularly radioresistant tumor requires very high radiation dose deposition for palliation or even ablation; a 40Gy radiosurgical dose controlled only 50% of 9LGS (19) . Tumor responses to MRT on D 55 T 45 in our study were markedly heterogeneous Indeed, 2/5 rats did not exhibit tumors; 2 animals showed well-delimited small tumors and 1 rat had a large tumor invading the whole hemisphere. The cause for these different responses is not understood but these 5 rats displayed a common change in MRI, a cerebral edema in parts of the ipsilateral hemisphere exposed to both intersecting arrays. These results were supported by demonstration of infiltrates of monocytes/macrophages (Supplementary materials, Fig. e1 ) and of a strong disorganization and remodeling of the normal vascular network at this site. Normal vessels appeared tortuous and larger, an observation consistent with the significant increase in VSI at D 55 T 45 (+9.8%). Thin matricial entities, probably not perfused, were commonly observed.
RECA-1 labeling was inhomogeneous.
A gradual increase in VEGF expression was detected in tumoral and in normal tissues.
However, the kinetics and the amount of the protein produced seemed to depend on the radiation dose (exposure to uni-or bidirectional irradiation) and the status of the tissue (normal or tumoral).
VEGF, secreted e.g. in ischemia, stroke and after irradiation (20, 21) , is commonly induced in presence of hypoxia; changes in tumoral and normal brain oxygen saturation after MRT should thus be evaluated. VEGF in the ipsilateral hemisphere was detectable from the second day after MRT and reached levels comparable to those measured in non-irradiated tumors. Thus, VEGF is implied in cerebral response in the early phase after MRT but its role is not defined. The overexpression of VEGF after MRT could have increased blood vessel permeability and led to severe brain edema.
Since the size of the tumors did not change significantly between D 25 T 15 and D 55 T 45 , we assume that MRT-induced brain edema in the crossfired regions was the main cause of animal deaths in our study. These qualitative findings are consistent observations (16) that major histopathologic brain and vascular damage was confined to MRT beam-crossing regions, whereas only minor damage was apparent in zones of the brain irradiated unidirectionally (16) . A comprehensive and detailed quantitative brain damage index for the present study was not established. However, the histopathologic findings were comparable, despite the different irradiation modalities.
Cross-fired MRT , particularly efficient for tumor control, may require corticosteroid injections (22) to control ensuing brain edema. Further, recovery from radiation injury may be influenced by growth factors involved in cell renewal and differentiation of neural tissue, e.g. by VEGF. Thus, a brief therapy with VEGF can prevent or delay radiation myelopathy after spinal cord injury in rats (23) . Experimentally, inhibition of VEGF may increase local tumor control after irradiation, possibly by preventing tumor angiogenesis (21) .
The preferential effect of MRT on tumor vasculature may lead to further improvements.
Most importantly, the tumor targeting for MRT used preclinically must be improved and adapted to clinical standards. Irradiation fields must be limited to the tumor; image guided, non coplanar irradiations, which limit normal tissue damage, should be adopted (15, 24 
